Common Skin Reactions with Opdivo
Opdivo (nivolumab), a PD-1 inhibitor used for cancers like melanoma and lung cancer, frequently causes skin reactions due to immune system activation. These occur in up to 50-60% of patients, often within weeks of starting treatment.[1][2]
Rash is the most reported, affecting 20-40% of users—typically maculopapular (red, bumpy patches) or pruritic (itchy). It appears on the trunk, arms, or legs and is usually mild to moderate, resolving with topical steroids like hydrocortisone or oral antihistamines.[1][3]
Pruritus alone hits 10-30% of patients, sometimes without visible rash, and responds to moisturizers or low-dose steroids.[2]
Severe or Less Common Skin Issues
About 1-5% experience grade 3-4 reactions needing intervention, such as:
- Severe rash or exfoliative dermatitis, covering large body areas.
- Bullous disorders like Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), rare (<1%) but life-threatening, with blistering and skin peeling.[1][4]
- Vitiligo, a depigmentation in 5-10% of melanoma patients, often linked to better tumor response.[3]
- Other: Lichenoid eruptions, psoriasis flares, or alopecia in 5-15%.[2]
How Long Do They Last and When Do They Start?
Reactions often begin in the first 4-6 weeks but can emerge anytime. Most mild cases resolve in 1-4 weeks with supportive care; severe ones may require pausing Opdivo or switching therapies.[1][3]
Management and What Doctors Recommend
- Grade 1 (mild): Continue treatment; use emollients, antihistamines.
- Grade 2 (moderate): Hold dose, add topical/oral steroids.
- Grade 3+: Discontinue permanently if unresolved; consider immunosuppressants like infliximab.[1][4]
Oncologists monitor via skin exams; premedication isn't standard but early intervention cuts severity.[2]
Why Do These Happen with Opdivo?
As a checkpoint inhibitor, Opdivo unleashes T-cells against tumors but can attack healthy skin, causing immune-related adverse events (irAEs). Risk rises with combo therapy (e.g., Opdivo + Yervoy).[3][4]
Compared to Other Immunotherapies
Opdivo has similar rates to Keytruda (pembrolizumab)—rash in ~30-40% vs. Opdivo's 25-35%—but higher with dual PD-1/CTLA-4 blockade.[2] Chemo drugs cause different rashes (e.g., hand-foot syndrome).
[1]: Opdivo Prescribing Information (BMS)
[2]: NCCN Guidelines: Melanoma (2023)
[3]: NEJM Review: Immune-Related Adverse Events (2018)
[4]: FDA Adverse Event Reporting System (FAERS) Summary